| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 06/15/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/01/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6.2% stake in AnaptysBio Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 8.4% stake in ANAPTYSBIO, INC. |
| 01/10/2023 |
4
| Ware J. Anthony (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| Topper James N (10% Owner) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| Schmid John P. (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| RENTON HOLLINGS (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| MULROY DENNIS (CFO) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 57,260 options to buy
@ $23.23, valued at
$1.3M
Granted 20,980 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| Marquet Magda (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| LOUMEAU ERIC J (COO, General Counsel) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 60,530 options to buy
@ $23.23, valued at
$1.4M
Granted 22,180 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| Lizzul Paul F. (Chief Medical Officer) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 67,070 options to buy
@ $23.23, valued at
$1.6M
Granted 24,580 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| Hamill Laura (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| FENTON DENNIS M (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 10,600 options to buy
@ $23.23, valued at
$246.2k
Granted 3,900 restricted stock units
@ $0 |
|
| 01/10/2023 |
4
| Faga Daniel (Interim CEO) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 194,900 options to buy
@ $23.23, valued at
$4.5M
Granted 71,400 restricted stock units
@ $0 |
|
| 01/05/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 11/08/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|